An experienced management team with a proven track record of drug approvals

A balanced portfolio of proprietary clinical drug candidates

Circulating Tumor Cells (CTCs) express biomarkers which may:

• Provide prognostic/predictive value for disease outcome and response to therapy
• Allow stratification of patients for enrollment in clinical trials based on levels of drug target
• Enable monitoring of patient response to therapy
• Allow profiling of metastatic disease which is otherwise difficult to access